

**“Genética e Hígado: Cómo contribuye la genética en el algoritmo diagnóstico de la enfermedad hepática pediátrica?”**

**Nicholas Ah Mew, MD**  
**April 24, 2017**

**SAP 2017**  
**Buenos Aires**

## 'Genetic disorders are rare – why do I need to consider them?'

- 30-50% of liver disease in children < 5y were due to a genetic etiology
- The younger the patient, the more likely a genetic etiology
- Focus on metabolic disorders for which treatments are available
  - Disorders of intermediary metabolism
  - All are autosomal recessive disorders

# Categories of metabolic liver disease

- Hepatocellular dysfunction
- Hepatosplenomegaly
- Cholestasis
- Recurrent Hypoglycemia

# Categories of metabolic liver disease

- Hepatocellular dysfunction
- Hepatosplenomegaly
- Cholestasis
- Recurrent Hypoglycemia

# Hepatocellular dysfunction


- Galactosemia
- Tyrosinemia
- Urea cycle disorders
- Mitochondrial DNA depletion syndromes
- Valproate induced liver disease
- Bile acid synthetic disorders
- Mevalonic aciduria
- Wilson's disease

## King's college study (2005-2015)

36 of 127 with acute liver failure had metabolic cause:

- **Galactosemia:** 17
- Mitochondrial disorder: 7
- **Urea cycle disorder:** 4
- **Tyrosinemia type I:** 4
- Niemann-Pick disease type C: 3
- Disorder of glycosylation: 1

# Galactose metabolism – the Leloir pathway



Galactose-1-Phosphate UridylTransferase

## Galactosemia - Clinical features

- Failure to thrive
- Liver dysfunction
- Jaundice (unconjugated → conjugated)
- E-coli sepsis
  
- Learning difficulties
- Primary ovarian insufficiency



# Galactosemia - Diagnosis

- Urine reducing substances
  - Identifies excess sugars in urine
  - If no glycosuria, suggestive of Galactosemia
- Diagnostic testing:
  - ↓ Erythrocyte GALT enzyme activity <10-15% activity
  - ↑ Erythrocyte Galactose-1-Phosphate
- DNA sequencing
- Pitfalls of newborn screening:
  - False positives in summer: GALT is a heat-sensitive enzyme
  - Duarte variant: ~25% of enzyme activity


# Galactosemia - Case presentation

- 1 month-old boy, missed newborn screen
  - AST: 292 U/L (3-34)
  - ALT: 115 U/L (15-41)
  - INR: 2.8 (0.8-1.2)
  - PTT: 55 (23-36)
  - Total Bilirubin: 9 mg/dl (0.2-1.3)
  - Direct Bilirubin: 5 mg/dl(<0.3)
- Liver transplant
  - Does not completely correct blood galactose levels

# Galactosemia - Management

- Avoidance of dietary galactose
  - Avoid lactose
  - Avoid breastmilk AND milk-based formulas
- Annual ophthalmologic exam

# Tyrosinemia type I (Hepatorenal tyrosinemia)



# Tyrosinemia Type I - Pathophysiology

- Deficiency of Fumarylacetoacetase
- ↑ Fumarylacetoacetate (FAA), Maleylacetoacetate (MAA), **Succinylacetone (SA)**
  - Disrupt glutathione metabolism
  - Alkylating agents

# Tyrosinemia Type I – Clinical Features

- 'Hepatorenal tyrosinemia'
- Acute liver failure
  - Liver synthetic function first/most affected
- Cirrhosis, Hepatocellular Carcinoma
- Renal: Proximal Tubular Disease
  - Renal Tubular Acidosis, Fanconi, glycosuria
  - Hypophosphatemic rickets

# Tyrosinemia Type I Diagnostic tests

- Plasma amino acids
  - Marked and disproportionately elevated tyrosine
- Urine succinylacetone present
  - Differentiates from other tyrosinemias and transient newborn tyrosinemia
- DNA sequencing

# Tyrosinemia Type I - Case presentation

6 week-old girl, newborn screening for tyrosinemia I

- AST = 93 U/L(16-61)
- ALT = 41 U/L (23-61)
- Total bilirubin = 0.8 mg/dl (<0.8)
- INR = 3.74 (0.88-1.14)
  
- Urinalysis: 2+ glucose, 1+ protein
- Plasma tyrosine = 627  $\mu$ mol/L (27-108)
- Positive urine succinylacetone




# Tyrosinemia Type I – Clinical Features

- Acute Neurological Crises
  - Results because succinylacetone inhibits 5-ALA dehydratase (heme synthesis)
  - Accumulation of neurotoxic 5-ALA
  - Painful paresthesias, autonomic signs (e.g., low blood pressure, difficulty urinating, sweating abnormalities)

# Tyrosinemia Type I - Treatment

- Dietary Protein (Tyrosine) restriction
- NTBC (Nitisinone, 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione)




# Tyrosinemia Type I - Treatment


- Dietary Protein (Tyrosine) restriction
- NTBC (Nitisinone, 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione)
  - Titrate until plasma succinylacetone is absent
- Even on treatment: Risk of hepatocellular carcinoma
  - AFP - every 3 months
  - Liver sonogram - yearly
  - Liver transplantation

## Urea cycle disorders

- Results from defect in one of 6 enzymes or 2 transporter needed for conversion of ammonia into urea
- This can result in
  - 1) Build up of ammonia
  - 2) Accumulation of intermediates



# The hepatic urea cycle



# Diagnosis of urea cycle disorders

- Hyperammonemia
- Plasma amino acid abnormalities
- ↑ Urine orotic acid
  
- DNA sequencing
- Hepatic (or erythrocyte) enzyme testing

## Urea cycle disorder – Case Presentation


- 1 ½ year-old girl, 1 month history of emesis and changes in sleep pattern
- Laboratory investigations:
  - ALT=1797 U/L
  - AST=784 U/L
  - INR = 4.0
  - Total bilirubin = 0.5 mg/dL
  - Ammonia = 225 µmol/L
  - Abnormal plasma amino acid profile
  - Elevated urine orotic acid



# Urea cycle disorders - Management

- Protein-restricted diet
- Alternative pathway medications
- Avoidance of prolonged fasting

# Hereditary fructose intolerance – inhibition of glycolysis and gluconeogenesis



# Hereditary Fructose Intolerance – Diagnostic features

- Nausea
- Vomiting
- Abdominal distress
- Failure to thrive
- Dietary avoidance of fructose
  
- Hypoglycemia
- Hyperlactatemia
- Hyperuricemia
- Renal tubular dysfunction

# Hereditary Fructose Intolerance - Diagnosis and management

## Diagnosis:

- Medical History
- Fructose challenge
- DNA sequencing
- Hepatic enzyme analysis

Management: avoidance of fructose, sucrose, sorbitol

# Hepatocellular dysfunction – Diagnostic investigations

- Plasma amino acid profile
- Urine organic acid profile
  - (succinylacetone, orotic acid)
- Urine reducing substances
- Galactose-1-Phosphate and GALT enzyme level

# Categories of metabolic liver disease

- Hepatocellular dysfunction
- Hepatosplenomegaly
- Cholestasis
- Recurrent Hypoglycemia


# Hepatosplenomegaly

Lysosomal storage disorders:

- Gaucher
- Niemann-Pick type A/C
- GM1 gangliosidosis
- Sialidosis type II
- I-cell
- Galactosialidosis

Salla

# Gaucher Disease - Pathophysiology





# Gaucher Disease – Clinical Manifestations

- Hepatosplenomegaly
  - Cytopenias
  - Coagulation disorder
- Bone disease (type I)
  - Focal lytic or sclerotic lesions
  - Acute bone pain ('bone crises')
- Neurological disease (type II, III)
  - Deteriorating neurological disease

## Gaucher Disease – Diagnosis

- Bone marrow exam: lipid-engorged macrophages (non-specific)
- DNA sequencing
- Enzymatic testing of leukocyte glucocerebrosidase

# Gaucher Disease - Management

- Symptomatic treatments
- Bone Marrow Transplantation
- Enzyme Replacement Therapy
- Substrate Reduction Therapy

# Categories of metabolic liver disease

- Hepatocellular dysfunction
- Hepatosplenomegaly
- Cholestasis
- Recurrent Hypoglycemia



# Cholestasis

- Galactosemia
- Tyrosinemia
- Citrin deficiency
- Alpha-1-Antitrypsin
- Progressive Familial Intrahepatic Cholestasis
- Bile acid synthetic disorders
- Wolman
- Dubin Johnson
- Rotor

# Categories of metabolic liver disease

- Hepatocellular dysfunction
- Hepatosplenomegaly
- Cholestasis
- Recurrent Hypoglycemia

# Recurrent Hypoglycemia: Disorders of energy metabolism




# Recurrent Hypoglycemia – categories of disorders

- Glycogen storage disorders
- Gluconeogenesis disorders
- Fatty acid oxidation disorders



# Disorders of glycogen metabolism / gluconeogenesis



# Glycogen storage disorders

- Liver specific isoforms
  - 0, I, III, IV, VI, IX, XI
- Typically present at age 3-4 months:
  - Fasting hypoglycemia
  - Hepatomegaly (except GSD 0)
  - Ketosis (except GSD 1)
  - Fasting lactic acidosis (except GSD 0)
  - Hyperlipidemia (except GSD 0, IV)
  - Hyperuricemia (GSD I)

# Glycogen Storage Disorders - Treatment

- Avoidance of fasting
- Soy-based formula without fructose, sucrose, lactose
- Frequent overnight feeds or continuous feeds
- Uncooked corn starch or glytactin

# Glycogen Storage Disorders - Diagnosis

- Liver biopsy: Histology shows fat and glycogen without fibrosis
- Enzyme assay on snap-frozen liver tissue
- DNA sequencing


# Disorders of gluconeogenesis

- Fructose 1,6-bisphosphatase
- Phosphoenolpyruvate Carboxykinase
- Pyruvate Carboxylase
- (Glucose-6-phosphatase)


# Fructose 1,6-bisphosphatase deficiency

- Presents nearly identically to GSD I
  - Hepatomegaly
  - Elevated transaminases
  - Fasting hypoglycemia and hyperlactatemia
  - Hyperuricemia
  - Preserved response to glucagon

# Fatty acid oxidation - pathophysiology




# Different length fatty-acids require different enzymes




Long Chain Fatty Acid

VLCAD



Medium Chain Fatty Acid

MCAD




Short Chain Fatty Acid

SCAD



# Fatty acids require carnitine and carnitine transport



## Fatty acid oxidation disorders – Clinical presentation

- Fasting hypoglycemia
  - Reduced or absent ketones
- Elevated transaminases
- LCHAD: maternal presentation of acute fatty liver of pregnancy or hemolysis, elevated platelets and liver failure (HELLP syndrome)
- Cardiomyopathy or arrhythmias

# Fatty acid oxidation disorders - Diagnosis

- Urine ketones (during hypoglycemia)
- Acylcarnitine profile
- Free / Total carnitine
  
- DNA sequencing
- Enzymatic testing (hepatocytes, leukocytes)

# Fatty acid oxidation disorders - Management

- Fasting avoidance (not as severe as GSDs)
  - Dextrose Infusion if NPO
- Replacement of Carnitine
- Echocardiogram (yearly)

## Summary: Recurrent Hypoglycemia +/- elevated transaminases +/- hepatomegaly

### Disorders:

- Glycogen storage disorders
- Gluconeogenesis disorders
- Fatty acid oxidation disorders

### Investigations:

- Lactate
- Triglycerides
- Uric acid
- Acylcarnitine profile
- Free/total carnitine



Thank you!  
Questions?